Almonacid, Carlos
Fitas, Eunice
Sánchez-Covisa, Joaquín
Gutiérrez, Héctor
Rebollo, Pablo
Funding for this research was provided by:
This study was funded by AstraZeneca Farmacéutica Spain, S.A
Article History
Received: 4 March 2022
Accepted: 22 December 2022
First Online: 4 January 2023
Declarations
:
: The protocol of this study was approved by the Ethics Committee for medical research of the Hospital Clinic of Barcelona (HCB/2021/0362). As this was a retrospective study carried out with data from existing anonymized databases, no informed consent was required, and so it was waived by the Ethics Committee for medical research of the Hospital Clinic of Barcelona (HCB/2021/0362). This study was performed in accordance with ethical principles that are consistent with the Declaration of Helsinki (current version: Fortaleza, Brazil, October 2013), ICH GCPs, GPP and the applicable legislation on Non-Interventional Studies and/or Observational Studies, specifically the Royal Decree 957/2020, of November 3rd, which regulates observational studies with medicines for human use.
: Not applicable.
: Carlos Almonacid declares that he has participated in speaking activities, advisory committees and consultancies during the period 2017–2021 sponsored by: AstraZeneca, Boehringer-Ingelheim, Chiesi, Menarini, GSK, ALK Mundipharma, Novartis, Pfizer, TEVA, SEPAR and NEUMOMADRID. Carlos Almonacid also declares not receiving ever, directly or indirectly, funding from the tobacco industry or its affiliates. Eunice Fitas and Joaquín Sánchez-Covisa were employees of AstraZeneca Farmacéutica S.A. Héctor Gutiérrez-Prieto and Pablo Rebollo were employees of IQVIA who received an honorarium from AstraZeneca in connection with the development of this manuscript.